These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35340663)

  • 1. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.
    Hein K; Short N; Jabbour E; Yilmaz M
    Blood Lymphat Cancer; 2022; 12():7-16. PubMed ID: 35340663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRD in ALL: Optimization and Innovations.
    Pierce E; Mautner B; Mort J; Blewett A; Morris A; Keng M; El Chaer F
    Curr Hematol Malig Rep; 2022 Aug; 17(4):69-81. PubMed ID: 35616771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
    Short NJ; Jabbour E
    Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
    Saygin C; Cannova J; Stock W; Muffly L
    Haematologica; 2022 Dec; 107(12):2783-2793. PubMed ID: 36453516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.
    Tran V; Salafian K; Michaels K; Jones C; Reed D; Keng M; El Chaer F
    Curr Hematol Malig Rep; 2024 Aug; 19(4):186-196. PubMed ID: 38888822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.
    Abou Dalle I; Jabbour E; Short NJ
    Ther Adv Hematol; 2020; 11():2040620720910023. PubMed ID: 32215194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.
    Sun YQ; Li SQ; Zhao XS; Chang YJ
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):453-464. PubMed ID: 32459519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
    Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
    Front Oncol; 2019; 9():726. PubMed ID: 31448230
    [No Abstract]   [Full Text] [Related]  

  • 10. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
    Logan AC
    Best Pract Res Clin Haematol; 2022 Dec; 35(4):101407. PubMed ID: 36517126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia.
    Davydova Y; Galtseva I; Kapranov N; Nikiforova K; Aleshina O; Chabaeva Y; Isinova G; Kotova E; Sokolov A; Troitskaya V; Kulikov S; Parovichnikova E
    Diagnostics (Basel); 2022 Dec; 13(1):. PubMed ID: 36611312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
    Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia.
    Akabane H; Logan A
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):413-422. PubMed ID: 32903253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.